| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 02/15/2007 | US20070036842 Non-woven scaffold for tissue engineering |
| 02/15/2007 | US20070036838 Methods and compositions for soothing oral and nasal tissues |
| 02/15/2007 | US20070036835 Hermetically Sealed Devices for Controlled Release or Exposure of Reservoir Contents |
| 02/15/2007 | US20070036834 Antiviral or anticancer for cancer or AIDS treatment; delivering said agents to the systemic circulation through vaginal or buccal mucosa |
| 02/15/2007 | US20070036831 Nanoemulsion compositions having anti-inflammatory activity |
| 02/15/2007 | US20070036830 Container |
| 02/15/2007 | US20070036829 Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye |
| 02/15/2007 | US20070036808 Cancer antigen peptide formulations |
| 02/15/2007 | US20070036764 Selective killing of cells by activation of double-stranded RNA dependent protein kinase-PKR |
| 02/15/2007 | US20070036745 Polymeric materials, their preparation and use |
| 02/15/2007 | US20070036744 Treatment or prevention of respiratory viral infections with alpha thymosin peptides |
| 02/15/2007 | US20070036733 Sensation masking composition |
| 02/15/2007 | US20070036732 Stable topiramate formulations |
| 02/15/2007 | US20070036731 Topical Delivery with a Carrier Fluid |
| 02/15/2007 | US20070036730 Cellulose derivatives |
| 02/15/2007 | US20070036720 Radiolabelled metal transport protein as imaging agent |
| 02/15/2007 | DE112005000708T5 Ionen bindende Zusammensetzung Ion scavenging composition |
| 02/15/2007 | DE102005037630A1 Verfahren zur Herstellung von Teilchen aus pharmazeutischen Substanzen, Teilchen aus pharmazeutischen Substanzen sowie deren Verwendung A process for preparing particles of pharmaceutical substances, particles of pharmaceutical substances as well as their use |
| 02/15/2007 | DE10141651B4 Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung Transdermal therapeutic system (TTS) with the active ingredient fentanyl and process for its preparation |
| 02/15/2007 | CA2626174A1 Formulations and methods for enhancing the transdermal penetration of a drug |
| 02/15/2007 | CA2618977A1 Orally disintegratable tablet |
| 02/15/2007 | CA2618966A1 Bitterness-reducing agent |
| 02/15/2007 | CA2618600A1 Reducing post-operative adhesion formation with intraperitoneal glutamine |
| 02/15/2007 | CA2618264A1 Dosage forms with improved bioavailability |
| 02/15/2007 | CA2618255A1 Itraconazole compositions with improved bioavailability |
| 02/15/2007 | CA2618093A1 Composition and method for use in cartilage affecting conditions |
| 02/15/2007 | CA2618084A1 Microparticle compositions of the topoisomerase i inhibitor 7-tert-butoxyiminomethylcamptothecin |
| 02/15/2007 | CA2617934A1 Transdermal drug delivery formulation |
| 02/15/2007 | CA2617909A1 Compositions exhibiting improved flowability |
| 02/15/2007 | CA2617873A1 Formulations for 7-(t-butoxy)iminomethyl camptothecin |
| 02/15/2007 | CA2617715A1 Pharmaceutical composition comprising a dpp-iv inhibitor |
| 02/15/2007 | CA2617280A1 Pharmaceutical form with sustained ph-independent active ingredient release for active ingredients having strong ph-dependent solubility |
| 02/15/2007 | CA2617160A1 Method for treating skin irritations such as diaper rash and the like |
| 02/15/2007 | CA2617101A1 Method for the protection against the risk of cardiac disorders comprising administration of tiotropium salts |
| 02/15/2007 | CA2616112A1 Oral suspension of prednisolone acetate |
| 02/15/2007 | CA2615941A1 Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor |
| 02/15/2007 | CA2615775A1 Controlled release of hypnotic agents |
| 02/15/2007 | CA2612481A1 Stable pharmaceutical composition comprising linezolid form iv |
| 02/15/2007 | CA2612080A1 Immediate-release therapeutic systems for improved oral absorption of 7-[(e)-t-butyloxyiminomethyl] camptothecin |
| 02/15/2007 | CA2608788A1 Spot-on formulations for combating parasites |
| 02/14/2007 | EP1752189A2 Microprojection array having a beneficial agent containing coating |
| 02/14/2007 | EP1752164A1 Percutaneous pharmaceutical preparation for external use containing nonsteroidal antiinflammatory analgesic |
| 02/14/2007 | EP1752152A1 Agent for visualizing transparent tissue |
| 02/14/2007 | EP1752150A1 Irinotecan preparation |
| 02/14/2007 | EP1752142A2 Pegylated nanoparticles |
| 02/14/2007 | EP1752141A1 Immune response stimulating composition comprising nanoparticles based on a methyl vinyl ether-maleic acid copolymer |
| 02/14/2007 | EP1752140A1 Method for banding hard capsules using hydroxypropylmethyl cellulose (HPMC) as a base |
| 02/14/2007 | EP1752139A1 Stable liquid formulation of paracetamol |
| 02/14/2007 | EP1752137A2 Hydrophilic or ambiphilic bases and compositions |
| 02/14/2007 | EP1752127A1 Process for producing edible oral administration preparation of aggregated substance-containing laminated film, and edible oral administration preparation of aggregated substance-containing laminated film |
| 02/14/2007 | EP1751245A1 Azeotrope-like compositions of tetrafluoropropene and hydrofluorocarbons |
| 02/14/2007 | EP1751225A2 Thermoplastic films and methods for making |
| 02/14/2007 | EP1750862A2 Pharmaceutical composition containing irbesartan |
| 02/14/2007 | EP1750769A2 Methods for making injectable polymer hydrogels |
| 02/14/2007 | EP1750768A2 Use of targeted oxidative therapeutic formulation in bone regeneration |
| 02/14/2007 | EP1750767A1 Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| 02/14/2007 | EP1750765A2 Antimycobacterial pharmaceutical composition comprising an antitubercular drug |
| 02/14/2007 | EP1750756A2 Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
| 02/14/2007 | EP1750750A1 Method of stabilizing proteins |
| 02/14/2007 | EP1750733A1 METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII |
| 02/14/2007 | EP1750725A1 Compositions comprising mannose phosphate for vaginal treatment |
| 02/14/2007 | EP1750718A1 Acyclovir formulations |
| 02/14/2007 | EP1750717A2 Controlled release pharmaceutical compositions with improved bioavailability |
| 02/14/2007 | EP1750688A1 Steroid intraocular implants having an extended sustained release for a period of greater than 2 months |
| 02/14/2007 | EP1750685A2 Anti-microbial handle system |
| 02/14/2007 | EP1750684A1 Dermal system of two patches detachably secured to each other for providing therapy to an area of the body |
| 02/14/2007 | EP1750683A1 Sustained release formulations |
| 02/14/2007 | EP1750682A2 Nutritional formulations |
| 02/14/2007 | EP1750681A2 Decontaminant edible product, methods of production and uses thereof |
| 02/14/2007 | EP1750680A2 Controlled release press-coated formulations of water-soluble active agents |
| 02/14/2007 | EP1750679A1 Gel composition comprising charged polymers |
| 02/14/2007 | EP1750678A2 Dosage form for delivery of multiple drug forms |
| 02/14/2007 | EP1750677A1 Oral therapeutic compound delivery system |
| 02/14/2007 | EP1750676A2 Ingestible device platform for the colon |
| 02/14/2007 | EP1750675A1 Stable oral pharmaceutical compositions of buprenorphine and derivatives |
| 02/14/2007 | EP1750674A2 Microparticles for oral delivery |
| 02/14/2007 | EP1750673A2 Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof |
| 02/14/2007 | EP1750672A2 Encapsulated transfer factor compositions and methods of use |
| 02/14/2007 | EP1750671A1 Liposomal assembly for therapeutic and/or diagnostic use |
| 02/14/2007 | EP1750670A1 Buccal, polar and non-polar sprays containing propofol |
| 02/14/2007 | EP1750669A1 Solid pharmaceutical form comprising an ltb4 antagonist |
| 02/14/2007 | EP1750668A1 Liquids containing suspended glass particles |
| 02/14/2007 | EP1750667A2 Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections |
| 02/14/2007 | EP1750666A2 Methods and articles for the delivery of therapeutic agents |
| 02/14/2007 | EP1750665A1 Biodegradable intravitreal tyrosine kinase inhibitors implants |
| 02/14/2007 | EP1750664A1 Intravitreal implants in conjunction with photodynamic therapy to improve vision |
| 02/14/2007 | EP1750662A1 Foamed cleanser with suspended particles, a method of producing same, and a dispenser therefore |
| 02/14/2007 | EP1750647A1 Pharmaceutical tablets having a separation mark positioned on the side of said tablets |
| 02/14/2007 | EP1680128B1 Myo-inositol hexaphosphate for topical use |
| 02/14/2007 | EP1575563B1 Non-hygroscopic formulation comprising a hydroscopic drug |
| 02/14/2007 | EP1507514B1 Controlled release compositions of estradiol metabolites |
| 02/14/2007 | EP1505956B1 A method to improve surface properties of pharmaceutical tablets |
| 02/14/2007 | EP1494629B1 Condom |
| 02/14/2007 | EP1485818B1 Treatment protocol generation for diseases related to angiogenesis |
| 02/14/2007 | EP1485059B1 Topical dapsone for the treatment of acne |
| 02/14/2007 | EP1443982B1 Porous polymeric prostheses and methods for making same |
| 02/14/2007 | EP1414409B1 Stabilized oral suspension formulation |
| 02/14/2007 | EP1392756B1 Lipid-polymer-conjugates |
| 02/14/2007 | EP1339701B1 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors |
| 02/14/2007 | EP1287824B1 Member for application of ointment and ointment patch employing the same |